JP2010511674A - 抗hiv化合物の臭化水素酸塩 - Google Patents
抗hiv化合物の臭化水素酸塩 Download PDFInfo
- Publication number
- JP2010511674A JP2010511674A JP2009539752A JP2009539752A JP2010511674A JP 2010511674 A JP2010511674 A JP 2010511674A JP 2009539752 A JP2009539752 A JP 2009539752A JP 2009539752 A JP2009539752 A JP 2009539752A JP 2010511674 A JP2010511674 A JP 2010511674A
- Authority
- JP
- Japan
- Prior art keywords
- compound
- formula
- solid dispersion
- hiv
- polymer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 title claims description 71
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 title abstract description 8
- 230000036436 anti-hiv Effects 0.000 title description 2
- 239000007962 solid dispersion Substances 0.000 claims abstract description 30
- 229940079593 drug Drugs 0.000 claims description 28
- 239000003814 drug Substances 0.000 claims description 28
- 239000002552 dosage form Substances 0.000 claims description 23
- 229920000642 polymer Polymers 0.000 claims description 20
- 229920003169 water-soluble polymer Polymers 0.000 claims description 15
- 239000008194 pharmaceutical composition Substances 0.000 claims description 14
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 13
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 13
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 13
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical group OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 13
- 239000002775 capsule Substances 0.000 claims description 9
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 8
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 8
- 239000001267 polyvinylpyrrolidone Substances 0.000 claims description 6
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 claims 2
- 229930003427 Vitamin E Natural products 0.000 claims 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 claims 1
- 229940031705 hydroxypropyl methylcellulose 2910 Drugs 0.000 claims 1
- 229940046009 vitamin E Drugs 0.000 claims 1
- 235000019165 vitamin E Nutrition 0.000 claims 1
- 239000011709 vitamin E Substances 0.000 claims 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 abstract description 3
- 239000007909 solid dosage form Substances 0.000 abstract 1
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 36
- 239000000203 mixture Substances 0.000 description 36
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 27
- 239000002245 particle Substances 0.000 description 25
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 19
- 239000008108 microcrystalline cellulose Substances 0.000 description 19
- 229940016286 microcrystalline cellulose Drugs 0.000 description 19
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 19
- 238000009472 formulation Methods 0.000 description 18
- 239000002904 solvent Substances 0.000 description 15
- 241000725303 Human immunodeficiency virus Species 0.000 description 13
- 239000000546 pharmaceutical excipient Substances 0.000 description 12
- 238000001694 spray drying Methods 0.000 description 11
- 238000000034 method Methods 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 230000037396 body weight Effects 0.000 description 9
- 150000003839 salts Chemical class 0.000 description 9
- 239000007787 solid Substances 0.000 description 9
- 239000007921 spray Substances 0.000 description 8
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 7
- 239000004480 active ingredient Substances 0.000 description 7
- PYGWGZALEOIKDF-UHFFFAOYSA-N etravirine Chemical compound CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br PYGWGZALEOIKDF-UHFFFAOYSA-N 0.000 description 7
- 241001465754 Metazoa Species 0.000 description 5
- 229960002049 etravirine Drugs 0.000 description 5
- 239000011159 matrix material Substances 0.000 description 5
- 208000024891 symptom Diseases 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 241000282472 Canis lupus familiaris Species 0.000 description 4
- 208000031886 HIV Infections Diseases 0.000 description 4
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 4
- 239000007884 disintegrant Substances 0.000 description 4
- 239000004615 ingredient Substances 0.000 description 4
- 239000000843 powder Substances 0.000 description 4
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 208000037357 HIV infectious disease Diseases 0.000 description 3
- -1 HPMC2910 Polymers 0.000 description 3
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 description 3
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical group C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 3
- 239000001863 hydroxypropyl cellulose Substances 0.000 description 3
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 description 3
- 229920003132 hydroxypropyl methylcellulose phthalate Polymers 0.000 description 3
- 238000001727 in vivo Methods 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000015927 pasta Nutrition 0.000 description 3
- 239000006187 pill Substances 0.000 description 3
- 230000036470 plasma concentration Effects 0.000 description 3
- 230000000750 progressive effect Effects 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 2
- 206010001513 AIDS related complex Diseases 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 239000001856 Ethyl cellulose Substances 0.000 description 2
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 description 2
- 229940122313 Nucleoside reverse transcriptase inhibitor Drugs 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 229920002472 Starch Polymers 0.000 description 2
- 235000019888 Vivapur Nutrition 0.000 description 2
- GAMPNQJDUFQVQO-UHFFFAOYSA-N acetic acid;phthalic acid Chemical compound CC(O)=O.OC(=O)C1=CC=CC=C1C(O)=O GAMPNQJDUFQVQO-UHFFFAOYSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 239000011230 binding agent Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 235000010980 cellulose Nutrition 0.000 description 2
- 229920002678 cellulose Polymers 0.000 description 2
- 239000001913 cellulose Substances 0.000 description 2
- 238000013270 controlled release Methods 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 229920001249 ethyl cellulose Polymers 0.000 description 2
- 235000019325 ethyl cellulose Nutrition 0.000 description 2
- 238000001704 evaporation Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 229940031704 hydroxypropyl methylcellulose phthalate Drugs 0.000 description 2
- 229920000609 methyl cellulose Polymers 0.000 description 2
- 239000001923 methylcellulose Substances 0.000 description 2
- 239000002726 nonnucleoside reverse transcriptase inhibitor Substances 0.000 description 2
- 244000052769 pathogen Species 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 238000000634 powder X-ray diffraction Methods 0.000 description 2
- 238000005507 spraying Methods 0.000 description 2
- 235000019698 starch Nutrition 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 239000004094 surface-active agent Substances 0.000 description 2
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- ARCGXLSVLAOJQL-UHFFFAOYSA-N trimellitic acid Chemical compound OC(=O)C1=CC=C(C(O)=O)C(C(O)=O)=C1 ARCGXLSVLAOJQL-UHFFFAOYSA-N 0.000 description 2
- PAWALTXRSMCTAC-ODTHDHSBSA-N (2S)-2-[[(2R)-2-[[(2S)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[(2R)-2-[[(2R)-2-[[(2S)-2-[[(2S)-2-[[2-[(2-aminoacetyl)amino]acetyl]amino]propanoyl]amino]-3-hydroxypropanoyl]amino]-3-sulfanylpropanoyl]amino]-3-sulfanylpropanoyl]amino]-4-methylpentanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-3-sulfanylpropanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]amino]-3-sulfanylpropanoyl]amino]-3-(1H-imidazol-5-yl)propanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CS)NC(=O)[C@H](CS)NC(=O)[C@H](CO)NC(=O)[C@H](C)NC(=O)CNC(=O)CN)C(=O)N[C@@H](Cc1ccc(O)cc1)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](Cc1c[nH]cn1)C(O)=O PAWALTXRSMCTAC-ODTHDHSBSA-N 0.000 description 1
- GXQIDURPSWCNCO-UHFFFAOYSA-N 4-[6-amino-5-bromo-2-(4-cyanoanilino)pyrimidin-4-yl]oxy-3,5-dimethylbenzonitrile;hydrobromide Chemical compound Br.CC1=CC(C#N)=CC(C)=C1OC1=NC(NC=2C=CC(=CC=2)C#N)=NC(N)=C1Br GXQIDURPSWCNCO-UHFFFAOYSA-N 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 206010003591 Ataxia Diseases 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 208000014912 Central Nervous System Infections Diseases 0.000 description 1
- 229920002785 Croscarmellose sodium Polymers 0.000 description 1
- 206010012289 Dementia Diseases 0.000 description 1
- 208000016192 Demyelinating disease Diseases 0.000 description 1
- 206010012305 Demyelination Diseases 0.000 description 1
- 206010013887 Dysarthria Diseases 0.000 description 1
- 229920003148 Eudragit® E polymer Polymers 0.000 description 1
- 108010078851 HIV Reverse Transcriptase Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 1
- 241000713340 Human immunodeficiency virus 2 Species 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 229920001479 Hydroxyethyl methyl cellulose Polymers 0.000 description 1
- 208000007766 Kaposi sarcoma Diseases 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 1
- 229920002565 Polyethylene Glycol 400 Polymers 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 229920001213 Polysorbate 20 Polymers 0.000 description 1
- 229920003081 Povidone K 30 Polymers 0.000 description 1
- 229920003082 Povidone K 90 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- AOBORMOPSGHCAX-UHFFFAOYSA-N Tocophersolan Chemical compound OCCOC(=O)CCC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C AOBORMOPSGHCAX-UHFFFAOYSA-N 0.000 description 1
- XTXRWKRVRITETP-UHFFFAOYSA-N Vinyl acetate Chemical compound CC(=O)OC=C XTXRWKRVRITETP-UHFFFAOYSA-N 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- IYKJEILNJZQJPU-UHFFFAOYSA-N acetic acid;butanedioic acid Chemical compound CC(O)=O.OC(=O)CCC(O)=O IYKJEILNJZQJPU-UHFFFAOYSA-N 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 229920003144 amino alkyl methacrylate copolymer Polymers 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002585 base Substances 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 229920001222 biopolymer Polymers 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- NEDGUIRITORSKL-UHFFFAOYSA-N butyl 2-methylprop-2-enoate;2-(dimethylamino)ethyl 2-methylprop-2-enoate;methyl 2-methylprop-2-enoate Chemical compound COC(=O)C(C)=C.CCCCOC(=O)C(C)=C.CN(C)CCOC(=O)C(C)=C NEDGUIRITORSKL-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229920002301 cellulose acetate Polymers 0.000 description 1
- 208000025222 central nervous system infectious disease Diseases 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- 208000004209 confusion Diseases 0.000 description 1
- 238000010924 continuous production Methods 0.000 description 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 description 1
- 235000010947 crosslinked sodium carboxy methyl cellulose Nutrition 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 206010013395 disorientation Diseases 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 238000002296 dynamic light scattering Methods 0.000 description 1
- 239000012055 enteric layer Substances 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000001125 extrusion Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 150000002334 glycols Chemical class 0.000 description 1
- 230000036449 good health Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 239000002835 hiv fusion inhibitor Substances 0.000 description 1
- 239000004030 hiv protease inhibitor Substances 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 229920003063 hydroxymethyl cellulose Polymers 0.000 description 1
- 229940031574 hydroxymethyl cellulose Drugs 0.000 description 1
- 239000012729 immediate-release (IR) formulation Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229940042402 non-nucleoside reverse transcriptase inhibitor Drugs 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 235000019198 oils Nutrition 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 239000003002 pH adjusting agent Substances 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- JLFNLZLINWHATN-UHFFFAOYSA-N pentaethylene glycol Chemical compound OCCOCCOCCOCCOCCO JLFNLZLINWHATN-UHFFFAOYSA-N 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- XNGIFLGASWRNHJ-UHFFFAOYSA-L phthalate(2-) Chemical compound [O-]C(=O)C1=CC=CC=C1C([O-])=O XNGIFLGASWRNHJ-UHFFFAOYSA-L 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
- 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
- 229920000136 polysorbate Polymers 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 229940083082 pyrimidine derivative acting on arteriolar smooth muscle Drugs 0.000 description 1
- 150000003230 pyrimidines Chemical class 0.000 description 1
- 238000002398 sedimentation field-flow fractionation Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000008109 sodium starch glycolate Substances 0.000 description 1
- 229920003109 sodium starch glycolate Polymers 0.000 description 1
- 229940079832 sodium starch glycolate Drugs 0.000 description 1
- 239000006104 solid solution Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 229940032147 starch Drugs 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1629—Organic macromolecular compounds
- A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
Landscapes
- Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- AIDS & HIV (AREA)
- Molecular Biology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
【選択図】なし
Description
しくは運ばなければならないような多くの理由で望ましくない。高い投薬負担はまた、患者がその全用量を服用せず、従って、処方された投薬計画に従うことができない危険性も増す。処置の効果を減らすとともに、これはまた薬剤に耐性を持つようになる病原生物もしくはウイルスももたらし得る。
感染と関連する他の症状は、末梢神経障害、進行性全身性リンパ節腫(PGL)およびエイズ関連複合体(ARC)を含んでなる。
ドロキシメチルセルロース、ヒドロキシエチルセルロース、ヒドロキシプロピルセルロース、ヒドロキシブチルセルロース、ヒドロキシエチルメチルセルロース、ヒドロキシプロピルメチルセルロース(HPMC)、例えばHPMC2910、カルボキシメチルセルロース、フタル酸ヒドロキシプロピルメチルセルロース(HPMCP)、例えばHP50、酢酸コハク酸ヒドロキシプロピルメチルセルロース(HPMCAS)、酢酸トリメリト酸セルロース(CAT)、酢酸フタル酸ヒドロキシプロピルセルロース(HPCAP)、酢酸フタル酸ヒドロキシプロピルメチルセルロース(HPMCAP)、酢酸フタル酸メチルセルロース(MCAP)、およびその混合物、例えばヒドロキシプロピルセルロースとエチルセルロースの混合物が包含される。適当なポリマーにはまた、ポリビニルピロリドン、酢酸ビニルと共重合したポリビニルピロリドンであるコポリビドン、およびアミノアルキルメタクリレートコポリマー、例えばEudragit E(R)100(Roehm GmbH,Germany)も包含される。好ましくは、ポリマーはヒドロキシプロピルメチルセルロース(HPMC)、ポリビニルピロリドンもしくはコポリビドンである。特に好ましいヒドロキシプロピルメチルセルロースは、HPMC2910 5mPa.sである。特に好ましいポリビニルピロリドンは、PVP K12、PVP K30もしくはPVP K90であり、そして特に好ましいコポリビドンはPVP−co−VA64である。
もたらす。賦形剤が供給混合物に加えられるかどうかにかかわらず、これらはまた所望の投与形態物への調合中に得られる固体製薬学的組成物と混合することもできる。
JRS Pharmaから入手可能である微結晶性セルロース製品、特にVivapur(R)105(20μm)、Vivapur(R)101(50μm)、Emcocel(R)SP15(15μm)、Emcocel(R)50M 105(50μm)、Prosolv(R)SMCC50(50μm);
DMVから入手可能である微結晶性セルロース製品、特にPharmacel(R)105(20μm)、Pharmacel(R)101(50μm);
Blanverから入手可能である微結晶性セルロース製品、特にTabulose(Microcel)(R)101(50μm)、Tabulose(Microcel)(R)103(50μm);
Asahi Kasei Corporationから入手可能である微結晶性セルロース製品、例えばCeolus(R)PH−F20JP(20μm)、Ceolus(R)PH−101(50μm)、Ceolus(R)PH−301(50μm)、Ceolus(R)KG−802(50μm)
を含んでなる。
ビタミンE TPGSおよびポリソルベート、例えばTween 20(R)が包含される。典型的なpH調整剤は酸、例えばクエン酸もしくはコハク酸、塩基またはバッファーである。
I)の化合物の用量もしくはサブ用量は、特定量の化合物、典型的には約10〜約1000mg、約50〜約800mg、約100〜約500mg、約100〜約300mg、例えば約200mgもしくは約240mgの式(I)の化合物を含有する単位投与形態物として調合することができる。
式(A)の化合物、すなわち、4−[[4−アミノ−5−ブロモ−6−(4−シアノ−2,6−ジメチルフェニルオキシ)−2−ピリミジニル]アミノ]ベンゾニトリルをジクロロメタンに溶解し、そして水性臭化水素酸を加えた。混合物を蒸発乾固させ、(A)の臭化水素酸塩、すなわち、式(I)の化合物を生成せしめた。式(A)の化合物の他の付加塩は同様に得ることができ、そして以下の表1に示される。
試験した製剤当たり4匹のオスイヌを使用した。性別平均の±20%以内の全ての動物で、体重に従ってコンピューターで作製したランダムアルゴリズムにより動物を試験群にわたって無作為化した。動物が良い健康状態であることを保証するために処置の開始の前に健康調査を行った。イヌは、実験室条件下で処置の開始前に少なくとも5日の順応期間を受けた。制御された環境は、室内において保たれた。動物に実施例1の製剤を1回経口投与し、そして投与後12、24もしくは48時間の期間にわたって一定の間隔で軽いエーテル麻酔下で全ての動物から血液を集めた。
5mPa.sの濃度は、100mlのメタノール/ジクロロメタン当たり6.5gであった。
入口空気温度: 80℃
出口空気温度: 40〜55℃
溶液の流速: 12ml/分
空気圧: 1bar
製剤L
製剤Lを製造するために、118.6mgの式(I)の化合物を第一のビーカーにおいて750mlのメタノール/ジクロロメタン当たり6.5gの濃度でメタノール/ジクロロメタン50/50 v/v%に溶解した。第二のビーカーにおいて、234.8mgのHPMC2910 5mPa.sをメタノール/ジクロロメタン50/50 v/v%に溶解した。溶液中のHPMC2910 5mPa.sの濃度は、100mlのメタノール/ジクロロメタン当たり6.5gであった。次に2つの溶液を混合し、そして121mgのHMPC 5mPa.s上に噴霧した。得られる粉末をスウェーデン−オレンジカプセルに詰めた。製剤Lの1個のカプセル剤は118.6mgの式(I)の化合物を含有し、それは100mgの化合物(A)に相当する。
Claims (10)
- 水溶性ポリマーがヒドロキシプロピルメチルセルロース、ポリビニルピロリドン、コポリビドンおよびビタミンE TGPSから選択される請求項1の固体分散体。
- ポリマーがヒドロキシプロピルメチルセルロース2910 5cpsである請求項4の固体分散体。
- ポリマー対薬剤の比が9:1〜1:1の範囲内である請求項3〜5のいずれかの固体分散体。
- ポリマー対薬剤の比が3:1〜1:1の範囲内である請求項6の固体分散体。
- 請求項1もしくは請求項2の化合物または請求項3〜8のいずれかの固体分散体を含んでなる投与形態物。
- 投与形態物が錠剤もしくはカプセル剤から選択される請求項9の投与形態物。
- 約10%以下の、もしくは約5%以下の、もしくは約1%以下の結晶化度を有する請求項1の化合物。
- 請求項8もしくは9に記載の式(I)の化合物および担体を含んでなる製薬学的組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06125547.7 | 2006-12-06 | ||
EP06125547 | 2006-12-06 | ||
PCT/EP2007/063386 WO2008068299A2 (en) | 2006-12-06 | 2007-12-06 | Hydrobromide salt of an anti-hiv compound |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2010511674A true JP2010511674A (ja) | 2010-04-15 |
JP5464584B2 JP5464584B2 (ja) | 2014-04-09 |
Family
ID=37962213
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009539752A Active JP5464584B2 (ja) | 2006-12-06 | 2007-12-06 | 抗hiv化合物の臭化水素酸塩 |
Country Status (5)
Country | Link |
---|---|
US (2) | US20100041687A1 (ja) |
EP (1) | EP2104491B1 (ja) |
JP (1) | JP5464584B2 (ja) |
ES (1) | ES2624593T3 (ja) |
WO (1) | WO2008068299A2 (ja) |
Families Citing this family (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
UY31531A1 (es) * | 2007-12-17 | 2009-08-03 | Sales derivadas de 8-oxoadenina composiciones farmacéuticas que las contienen y su uso en terapia como moduladores de receptor tipo toll (tlr) | |
WO2010006697A2 (en) * | 2008-06-30 | 2010-01-21 | Tibotec Pharmaceuticals | Powders for reconstitution |
BRPI1012666B8 (pt) * | 2009-03-30 | 2021-05-25 | Janssen R&D Ireland | cocristal de etravirina e nicotinamida, composição farmacêutica, combinação compreendendo o mesmo, seu processo para a preparação e uso |
WO2010131118A2 (en) * | 2009-05-12 | 2010-11-18 | Pliva Hrvatska D.O.O. | Polymorphs of etravirine and processes for preparation thereof |
US8153790B2 (en) | 2009-07-27 | 2012-04-10 | Krizmanic Irena | Process for the preparation and purification of etravirine and intermediates thereof |
GR1007010B (el) | 2009-10-08 | 2010-10-07 | Χημικα Και Βιοφαρμακευτικα Εργαστηρια Πατρων Αε (Cbl-Patras), | Ινσουλινοειδη πεπτιδια |
WO2013059572A1 (en) | 2011-10-19 | 2013-04-25 | Assia Chemical Industries Ltd. | Process for the preparation of etravirine and intermediates in the synthesis thereof |
RU2728555C1 (ru) * | 2019-12-24 | 2020-07-30 | Общество с ограниченной ответственностью "Балтфарма" | Способ получения этравирина |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027825A1 (en) * | 1998-11-10 | 2000-05-18 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines |
WO2005011702A1 (en) * | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
EP1225874B1 (en) * | 1999-09-24 | 2006-02-01 | Janssen Pharmaceutica N.V. | Antiviral solid dispersions |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000003697A1 (en) * | 1998-07-17 | 2000-01-27 | Janssen Pharmaceutica N.V. | Pellets having a core coated with an antifungal and a polymer |
-
2007
- 2007-12-06 ES ES07847874.0T patent/ES2624593T3/es active Active
- 2007-12-06 US US12/517,665 patent/US20100041687A1/en not_active Abandoned
- 2007-12-06 JP JP2009539752A patent/JP5464584B2/ja active Active
- 2007-12-06 EP EP07847874.0A patent/EP2104491B1/en active Active
- 2007-12-06 WO PCT/EP2007/063386 patent/WO2008068299A2/en active Application Filing
-
2017
- 2017-10-27 US US15/795,873 patent/US11253479B2/en active Active
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000027825A1 (en) * | 1998-11-10 | 2000-05-18 | Janssen Pharmaceutica N.V. | Hiv replication inhibiting pyrimidines |
EP1225874B1 (en) * | 1999-09-24 | 2006-02-01 | Janssen Pharmaceutica N.V. | Antiviral solid dispersions |
WO2005011702A1 (en) * | 2003-07-17 | 2005-02-10 | Tibotec Pharmaceuticals Ltd. | Process for preparing particles containing an antiviral |
Non-Patent Citations (2)
Title |
---|
JPN6013021338; 11th Annual FDA Science Forum Poster Abstract , 200504, C-21 * |
JPN6013021340; J. Verbeeck et al.: Toxicology Letters Vol.158S, No.1, 2005, p.S211 * |
Also Published As
Publication number | Publication date |
---|---|
US20100041687A1 (en) | 2010-02-18 |
ES2624593T3 (es) | 2017-07-17 |
JP5464584B2 (ja) | 2014-04-09 |
WO2008068299A2 (en) | 2008-06-12 |
US20180049986A1 (en) | 2018-02-22 |
US11253479B2 (en) | 2022-02-22 |
EP2104491A2 (en) | 2009-09-30 |
EP2104491B1 (en) | 2017-02-22 |
WO2008068299A3 (en) | 2009-04-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US11253479B2 (en) | Hydrobromide salt of an anti-HIV compound | |
US7713548B2 (en) | Amorphous solid dispersions | |
EP2170289B1 (en) | Preparation method for solid disupersions | |
EP2931285A1 (en) | Pharmaceutical compositions | |
JP2010531301A (ja) | ダルナビル及びエトラビリンを含んでなる組み合わせ調剤 | |
JP5748737B2 (ja) | エトラビリンとニコチンアミドの共結晶 | |
TWI380829B (zh) | 具有改良的生物可利用率之普侖斯特(pranlukast)固態分散物組成物及製備該固態分散物之方法 | |
US20150104511A1 (en) | Pharmaceutical Antiretroviral Combinations Comprising Lamivudine, Festinavir and Nevirapine | |
JP5554571B2 (ja) | 復元用の粉剤 | |
WO2021146378A1 (en) | Compositions of substituted pyrazolopyrimidines and uses thereof | |
US9603803B2 (en) | Process for preparing spray dried formulations of 4-[[6-amino-5-bromo-2-[(4-cyanophenyl)amino]-4-pyrimidinyl]oxy]-3,5-dimethylbenzonitrile | |
JP2010536798A (ja) | 難溶性薬物の生体利用率を制御するための方法及び組成物 | |
AU2890999A (en) | Novel compositions of eprosartan | |
EP2306980A2 (en) | Powders for reconstitution | |
JP2018516942A (ja) | 生体利用率が改善された含プランルカスト固形製剤の組成物及びその製造方法 | |
WO2023220112A1 (en) | Glp1 tablet compositions |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20101203 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20130514 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130814 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130821 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20130913 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20130924 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20131015 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20131022 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20131114 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20140107 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20140115 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5464584 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
S111 | Request for change of ownership or part of ownership |
Free format text: JAPANESE INTERMEDIATE CODE: R313113 |
|
R350 | Written notification of registration of transfer |
Free format text: JAPANESE INTERMEDIATE CODE: R350 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |